What were the main drivers of Eli Lilly's sales growth in Q3 2003?

Sales growth was primarily driven by the strong performance of key established products such as Zyprexa, Humalog, Gemzar, and Evista. Additionally, newer product launches like Strattera, Cialis, and Forteo are beginning to contribute significantly to the company's top-line growth.

How did the company's profitability compare to the prior year, and what impacted the results?

For the third quarter of 2003, net income increased by 5% to $714.4 million due to higher sales and the absence of the $84 million acquired in-process R&D charge seen in Q3 2002. However, for the first nine months of 2003, net income decreased by 8% to $1.81 billion, primarily due to significant asset impairment, restructuring, and special charges totaling over $350 million incurred in the first quarter of 2003.

What is the company's outlook regarding patent litigation for its key products?

Eli Lilly is actively engaged in patent litigation concerning generic challenges to its blockbuster drugs Zyprexa and Evista. While the company believes these challenges are without merit and expects to prevail, it acknowledges that an unfavorable outcome could materially impact its financial results. The Zyprexa litigation is scheduled to begin in January 2004, and the Evista litigation trial is slated for February 2005.

How is Eli Lilly managing its R&D investments and product pipeline?

The company continues to make significant investments in research and development, with R&D expenses increasing by 8% for the quarter and 4% for the nine-month period. Key pipeline developments include seeking FDA approval for Cymbalta (expected summer 2004), Symbyax (early 2004), and additional indications for Zyprexa. The company is also working to resolve manufacturing issues to secure final approvals for some of these products.

LLY 10-Q Quarterly Report Q3 FY2003 — Revenue, Net Income, EPS

Summary

Eli Lilly and Company reported solid third-quarter 2003 results, with net sales increasing by 13% to $3.14 billion, driven by strong performance from key products like Zyprexa, Humalog, Gemzar, and Evista, as well as successful new launches including Strattera, Cialis, and Forteo. Despite a challenging comparable period in 2002 impacted by charges, the company demonstrated robust sales growth both in the U.S. and internationally, with international sales up 17% year-over-year. Financially, the company saw a 5% increase in net income for the quarter, reaching $714.4 million, with diluted EPS at $0.66, compared to $0.63 in the prior year. For the nine-month period, however, net income decreased by 8% to $1.81 billion, primarily due to significant asset impairment, restructuring, and special charges incurred in the first quarter of 2003. The company continues to invest in research and development, increasing R&D expenses by 8% for the quarter and 4% for the nine-month period, reflecting a strategic commitment to future growth. Lilly is also actively managing its capital structure, with a share repurchase program underway and a solid cash position, providing confidence in funding ongoing operations and strategic initiatives.

Key Highlights

1Total net sales for Q3 2003 increased by 13% to $3.14 billion compared to Q3 2002.
2Net income for Q3 2003 rose by 5% to $714.4 million, with diluted EPS at $0.66.
3Zyprexa sales saw a significant 16% increase year-over-year for the quarter, driven by strong international performance.
4New product launches including Strattera, Cialis, and Forteo are contributing positively to sales growth.
5The company incurred substantial asset impairment, restructuring, and special charges in Q1 2003, impacting nine-month net income negatively.
6Research and development expenses increased by 8% in Q3 2003, indicating continued investment in future growth drivers.
7Lilly maintained a strong cash position with $3.87 billion in cash, cash equivalents, and short-term investments as of September 30, 2003.

ELI LILLY & Co Quarterly Report for Q3 Ended Sep 30, 2003

Summary

Key Highlights

Frequently Asked Questions